Case Reports in Anesthesiology

Case Reports in Anesthesiology / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 1852016 |

Ahmed Abdelaal Ahmed Mahmoud, Mark Campbell, Margarita Blajeva, "Can ACE-I Be a Silent Killer While Normal Renal Functions Falsely Secure Us?", Case Reports in Anesthesiology, vol. 2018, Article ID 1852016, 4 pages, 2018.

Can ACE-I Be a Silent Killer While Normal Renal Functions Falsely Secure Us?

Academic Editor: Stefano Faenza
Received29 Jan 2018
Revised01 Jun 2018
Accepted19 Jun 2018
Published09 Jul 2018


The current case report represents a warning against serious hyperkalaemia and acidosis induced by ACE-I during surgical stress while normal renal function could deceive the attending anaesthetist. Arterial gas analysis for follow-up of haemoglobin loss accidentally discovered hyperkalaemia and acidosis. Glucose-insulin and furosemide successfully corrected hyperkalaemia after 25 minutes and acidosis after 3 hours. These complications could be explained by a deficient steroid stress response to surgery secondary to suppression by ACE-I. Event analysis and database search found that ACE-I induced aldosterone deficiency aggravated by surgical stress response with an inadequate increase in aldosterone secretion due to angiotensin II deficiency as a sequel of ACE-I leading to defective secretion of H+ and K+. Furosemide is recommended to secrete H+ and K+ compensating for aldosterone deficiency in addition to other antihyperkalaemia measures. Anaesthetising an ACE-I treated patient requires considering ACE-I as a potential cause of hyperkalaemia and acidosis.

1. Introduction

We present a case of accidentally discovered, unexpected intraoperative acidosis and hyperkalaemia in an ACE-I treated patient with no renal impairment or diabetes. Written consent was obtained from the patient for publication.

It is not uncommon for the anaesthetists to manage a hypertensive patient treated with Angiotensin Converting Enzyme Inhibitors (ACE-I) scheduled for either elective or emergency surgery. ACE-I are well known to be associated with a potential risk of perioperative side effects and complications as intraoperative hypotension and need for vasopressors, preoperative hyperkalaemia, perioperative drug-induced angioedema, and possible postoperative hypertension [1].

The risk of hyperkalaemia in ACE-I treated patients is higher in patients with type II diabetes or renal insufficiency. At least 10% of patients treated with ACE-I will experience even mild hyperkalaemia during their course of treatment with ACE-I [2]. The mechanism of ACE-I associated hyperkalaemia is mainly due to aldosterone deficiency with resultant decreased effect of aldosterone on collecting tubules leading to reduced excretion of potassium and decreased sodium reabsorption [2, 3].

2. Case Description

A 59-year-old male was scheduled for elective open retropubic prostatectomy for a benign enlarged prostate weighing approximately 65 grams. The patient’s weight was 89 kg, ASA physical status II, diagnosed with essential hypertension two years ago, and controlled with ACE-I, Ramipril 10 mg once daily. No other morbidities were associated and no other medications were taken by the patient. The preoperative assessment did not reveal any other abnormality related to anaesthesia with normal vital signs, omitting Ramipril for 48 hours before the operation and normal baseline laboratory results including renal profile (creatinine 87 micromole/L, urea 7.9 mmol/L, Na 140 mmol/L, and K 4.1 mmol/L).

Following discussion with the patient and the surgical team, the anaesthetic plan was general anesthesia (GA) with postoperative patient-controlled analgesia (PCA) with morphine. Relatively uneventful induction of GA by propofol (2mg/kg), fentanyl (100 micrograms), and rocuronium (0.6 mg/kg) with endotracheal intubation, radial arterial cannulation for IBP monitoring, and two wide-bore peripheral cannulas (18G) were inserted. Induction was accompanied by hypotension (BP dropped from 112/68 to 73/46) and bradycardia (HR dropped from 78/min. to 38/min.) that required two successive doses of ephedrine each 6 mg were followed by restoration of BP and HR. Baseline arterial blood gas (ABG) after positioning was normal (Table 1). At 2 hours after the start of surgery, the estimated blood was about 350 ml and the urinary output (UOP) was 120 ml (over 2 hours) with mean arterial pressure (MAP) being maintained above 70 mmHg without further vasopressors required other than the initial 12 mg of ephedrine required immediately after induction. An arterial blood gas (2 hours after start of surgery) was initially performed for monitoring haemoglobin level showed hyperkalaemia (6.1 mmol/L) with acidosis (pH 7.33 and PCo2 6.2 kPa). The initial explanation was respiratory acidosis, and ventilation parameters were increased. Twenty-five minutes later ABG showed a decrease of PCo2 to normal with normal anion gap acidosis and increasing potassium to 6.5 mmol/L. Hyperkalaemia was treated with glucose-insulin (10 units of insulin added to 1 litre of glucose 10%) and mild hyperventilation and furosemide (20 mg bolus) with a change of the maintenance fluid from compound lactate solution to normal saline with the same rate (225ml/h). Forty minutes later, these measures had reduced potassium from 6.5 mmol/L to 4.1 mmol/L.


PCO2 (kPa)
PO2 (kPa)12.520.822.32620.815.511.7
sO2 (%)95979898989895
Base Excess(mmol/L)0-2-2-4-4-3-1
Standard Bicarbonate (mmol/L)24232321212223
Actual Bicarbonate (mmo/L)25242422222324
Total haemoglobin (g/dl)12.91312.9119.810.410.5
Carboxyhaemoglobin (%)
Whole blood glucose (mmol/L)5.97.1816.
Methaemoglobin (%)
Sodium (mmol/L)139137136133138138138
Potassium (mmol/L)
Lactate (mmol/L)

Despite normalization of potassium level (k 4.1 mmol/L) following the measures mentioned above, the acidosis persisted with maintained normal bicarbonate level and normal PCo2 (Table 1). From the time of normalized potassium, the acidosis required three hours to normalize which was two hours after recovery from GA. The presence of acidosis did not affect emergence from anaesthesia or recovery of the patient.

Postoperative follow-up of the renal function tests and electrolytes (Table 2) revealed normalization over a period of two days postoperatively with the patient restored intake of ACE-I on day one postoperatively with no effect on potassium level.

Renal function testPreoperativeDay 1 postoperativeDay 2 postoperative

Sodium (mmol/L)140141140
Potassium (mmol/L)
Creatinine (umol/L)879985
Urea (mmol/L)

: estimated glomerular filtration rate, calculated by Cockcroft and Gault modified equation.

At the end of surgery, the estimated blood loss was about 635 ml, UOP was 700 ml (over an operative time of 4 hours), and the infused fluids included 450 ml of Hartman's solution (over the first 2 hours), 950 ml of 0.9% normal saline, and 500 ml of Gelofusine 4% (over the second 2 hours) in addition to 1 litre of glucose 10% with insulin. No blood transfusion was required and no MAP <70 mmHg was recorded.

3. Discussion

Systematic analysis of the event did not reveal any cause for the hyperkalaemia and acidosis except the history of treatment with ACE-I that may be associated with renal tubular acidosis (RTA), normal anion gap acidosis, and hyperkalaemia [213]; this explanation was supported by results from database search [115] including the effect of furosemide in hyperkalaemic RTA [11].

The patient did not receive blood transfusion and did not experience hypotensive events apart from a single induction related hypotension event that was corrected by a small dose of ephedrine; this excludes the possibility of either transfusion related or acute kidney injury due to hypotension as possible causes of hyperkalaemia. A single dose of propofol was used for induction of anaesthesia making the possibility of propofol infusion syndrome extremely unlikely.

The steroid hormone aldosterone acts on a mineralocorticoid receptor in the renal collecting ducts through a protein kinase mechanism leading to stimulation of Na+ reabsorption and active secretion of both H+ and K with potential risk for hyperkalaemia and acidosis in case of aldosterone deficiency [4, 5].

Angiotensin II is essential for the secretion of aldosterone [5] with ACE-I can produce a variable degree of hyporeninemic hypoaldosteronism or type IV renal tubular acidosis [610] characterized by metabolic acidosis and hyperkalaemia due to aldosterone deficiency.

Furosemide can be beneficial in type IV renal tubular acidosis by stimulation of K+ and H+ secretion from distal collecting tubules in case of hypoaldosteronism [11].

Typically, surgical induced stress response is associated with increased secretion of cortisol and aldosterone through stimulation of the hypothalamic-pituitary-adrenocortical axis (HPA-axis) with subsequent electrolyte changes including salt and water retention with hypokalaemia [12].

Experimental research demonstrated that angiotensin II and ACE could intervene with the pituitary hormones secretion like corticotropin (ACTH) and enhances the stimulatory effects of corticotropin-releasing hormone (CRH), thus contributing to the stress-related activation of the hypothalamic-pituitary-adrenocortical (HPA) axis [13, 14]. Subsequently the inhibition of ACE with ACE-I will be associated decreased stress response, and with reduced cortisol secretion, this can aggravate the risk of hyperkalaemia and acidosis in ACE-I treated patients when exposed to surgical stress response (Figure 1).

Although, our patient stopped ACE-I 48 hours before surgery, it has been proved that aldosterone level does not change up to 15 days after cessation of Ramipril [16]. This augments the explanation that the hyperkalaemia can be due to the residual effect of ACE-I on aldosterone level.

It is known that renal impairment and diabetes can be associated with increased risk of hyperkalaemia and acidosis in ACE-I treated patients who may warn the anaesthetists to suspect, monitor, and detect such complication; however, we reported a case of unexpected hyperkalaemia and acidosis in a surgical patient treated with ACE-I with normal baseline renal function, with adequate response to dextrose insulin and furosemide and correction of both hyperkalaemia and acidosis. This event in our case report may be triggered by surgical stress response with deficient steroid secretion especially aldosterone; this is supported by the ability of furosemide to reverse the effects of aldosterone deficiency by secreting hydrogen ion and potassium.

Although the lactate level increased during the surgery, this cannot be explained by increased production as no haemodynamic instability was recorded but may be related to impaired excretion of lactate as a part of renal tubular acidosis.

The current patient experienced a mild increase in creatinine level and a mild drop in in glomerular filtration rate. The derangement in renal function postoperatively may be due to the use of furosemide intraoperatively, which has been recorded before to produce drop GFR [17].

Acidosis persisted despite potassium normalization with insulin, until successful correction was achieved with the diuretic effect of furosemide. Insulin administration produced correction of potassium but not acidosis as insulin may participate to acidosis [18] and this supports the fact that acidosis in our case was most probably due to the fact that renal tubular acidosis was induced by the preoperative use of ACE-I.

The possibility that catecholamines may shifted potassium intracellularly is not possible as catecholamines are also suppressed with ACE-I [19]

Patients on ACE-I are recommended for perioperative monitoring of potassium for early detection and management of such possible complications especially with unexplained ECG signs of hyperkalaemia and haemodynamic instability. In case of developing hyperkalaemia and acidosis, furosemide is recommended to secrete H+ and K+ compensating for aldosterone deficiency in addition to other antihyperkalaemia measures.

A limitation in our case report is that we did not measure the aldosterone level after the event.

4. Future Research

No previous studies [15] examined the effect of ACE-I on potassium and hydrogen ion during the surgical stress response; additionally, no information is available if ACE-I treated patients have a normal cortisol stress response or not in the perioperative period.

A future research study can assess the risk of hyperkalaemia and acidosis during the operative period in patients treated with ACE-I in addition to assessment of cortisol stress response in this category of patients.

Conflicts of Interest

No conflicts of interest declared by any of the authors.

Authors’ Contributions

Ahmed Abdelaal Ahmed Mahmoud contributed to writing the manuscript. Mark Campbell revised the final manuscript. Margarita Blajeva collected data of the patient. All the three authors were involved in the clinical management of the case described.


  1. B. Mets, “To stop or not?” Anesthesia & Analgesia, vol. 120, no. 6, pp. 1413–1419, 2015. View at: Publisher Site | Google Scholar
  2. M. A. Raebel, “Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers,” Cardiovascular Therapeutics, vol. 30, no. 3, pp. e156–e166, 2012. View at: Publisher Site | Google Scholar
  3. L. C. Reardon and D. S. Macpherson, “Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: How much should we worry?” JAMA Internal Medicine, vol. 158, no. 1, pp. 26–32, 1998. View at: Publisher Site | Google Scholar
  4. W. Thomas and B. J. Harvey, “Mechanisms Underlying Rapid Aldosterone Effects in the Kidney,” Annual Review of Physiology, vol. 73, no. 1, pp. 335–357, 2011. View at: Publisher Site | Google Scholar
  5. J. H. Pratt, J. K. Rothrock, and J. H. Dominguez, “Evidence that angiotensin-II and potassium collaborate to increase cytosolic calcium and stimulate the secretion of aldosterone,” Endocrinology, vol. 125, no. 5, pp. 2463–2469, 1989. View at: Publisher Site | Google Scholar
  6. F. E. Karet, “Mechanisms in hyperkalemic renal tubular acidosis,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 251–254, 2009. View at: Publisher Site | Google Scholar
  7. M. Schambelan, A. Sebastian, and E. G. Biglieri, “Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency,” Kidney International, vol. 17, no. 1, pp. 89–101, 1980. View at: Publisher Site | Google Scholar
  8. A. G. Sousa, J. V. Cabral, W. B. El-Feghaly, L. S. Sousa, and A. B. Nunes, “Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management,” World Journal of Diabetes, vol. 7, no. 5, p. 101, 2016. View at: Publisher Site | Google Scholar
  9. R. Düsing and F. Sellers, “ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: A review of their role after the ONTARGET trial,” Current Medical Research and Opinion, vol. 25, no. 9, pp. 2287–2301, 2009. View at: Publisher Site | Google Scholar
  10. C. S. Haas, I. Pohlenz, U. Lindner et al., “Renal tubular acidosis type IV in hyperkalaemic patients - A fairy tale or reality?” Clinical Endocrinology, vol. 78, no. 5, pp. 706–711, 2013. View at: Publisher Site | Google Scholar
  11. S. Rastogi, J. M. Bayliss, L. Nascimento, and J. A. L. Arruda, “Hyperkalemic renal tubular acidosis: Effect of furosemide in humans and in rats,” Kidney International, vol. 28, no. 5, pp. 801–807, 1985. View at: Publisher Site | Google Scholar
  12. D. Burton, G. Nicholson, and G. M. Hall, “Endocrine and metabolic response to surgery,” Continuing Education in Anaesthesia, Critical Care and Pain, vol. 4, no. 5, pp. 144–147, 2004. View at: Publisher Site | Google Scholar
  13. I. Armando, S. Volpi, G. Aguilera, and J. M. Saavedra, “Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress,” Brain Research, vol. 1142, no. 1, pp. 92–99, 2007. View at: Publisher Site | Google Scholar
  14. M. G. Pavlatou, G. Mastorakos, I. Lekakis et al., “Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: Preliminary results,” Stress, vol. 11, no. 1, pp. 62–72, 2008. View at: Publisher Site | Google Scholar
  15. Z. Zou, H. B. Yuan, B. Yang et al., “Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults,” Cochrane Database of Systematic Reviews. View at: Publisher Site | Google Scholar
  16. D. Stephan, M. Grima, M. Welsch, M. Barthelmebs, D. Vasmant, and J. Imbs, “Interruption of prolonged ramipril treatment in hypertensive patients: Effects on the renin-angiotensin system,” Fundamental & Clinical Pharmacology, vol. 10, no. 5, pp. 474–483, 1996. View at: Publisher Site | Google Scholar
  17. H. Trivedi, T. Dresser, and K. Aggarwal, “Acute effect of furosemide on glomerular filtration rate in diastolic dysfunction,” Renal Failure, vol. 29, no. 8, pp. 985–989, 2007. View at: Publisher Site | Google Scholar
  18. J. M. Goguen and M. L. Halperin, “Can insulin administration cause an acute metabolic acidosis in vivo? - An experimental study in dogs,” Diabetologia, vol. 36, no. 9, pp. 813–816, 1993. View at: Publisher Site | Google Scholar
  19. A. V. Sidorov and M. M. J. Fateev, “Effect of angiotensin-converting enzyme inhibitors, beta-adrenoblockers and their combinations on survival and blood plasma catecholamine levels in rats with chronic heart failure with induced exacerbations,” Journal of Evolutionary Biochemistry and Physiology, vol. 49, 330 pages, 2013. View at: Publisher Site | Google Scholar

Copyright © 2018 Ahmed Abdelaal Ahmed Mahmoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.